Table 1.

Characteristics of the included studies.

Study	Country	Adjuvant TACE vs. Hepatectomy Only	Males	Age (Years)	CPS (A/B/C)	HBV (+)	Tumor Size (cm)	MVI	Anatomic Resection	TACE Regimen	TACE Frequency
Izumi 1994 [30]	Japan	23 vs. 27	44/50	63.6 ± 9.9	N/A	8/50	N/A	50/50	21/50	Lipidol, doxorubicin, mitomycin	Once
Lai 1998 [32]	China	30 vs. 36	53/66	54.0 ± 12.0	N/A	56/66	9.5 ± 11.6	N/A	60/66	Lipiodol, cisplatin	3 courses every 2 months
Li 1995 [31]	China	47 vs. 47	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Lipiodol, doxorubicin, mitomycin	1–3 courses every 4–6 weeks
Li 2006 (1) [33]	China	35 vs. 37	65/72	54.4 ± 10.6	33/39/0	63/71	9.8 ± 3.2	72/72	72/72	Lipiodol, doxorubicin, mitomycin, cisplatin, carboplatin	3 courses every 2 weeks
Li 2006 (2) [34]	China	39 vs. 45	73/84	51.6 ± 10.6	45/39/0	69/84	5.2 ± 1.7	N/A	84/84	Lipiodol, doxorubicin, mitomycin, cisplatin, carboplatin	3 courses every 2 weeks
Peng 2009 [35]	China	51 vs. 53	96/104	48.2 ± 11.2	90/14/0	71/104	8.7 ± 2.7	104/104	35/104	Lipiodol, 5-fluorouracil, doxorubicin	2–5 courses every 1–2 months
Wang 2018 [36]	China	140 vs. 140	230/280	53.4 ± 10.0	N/A	280/280	N/A	165/280	121/280	Lipidol, doxorubicin	N/A
Wei 2018 [37]	China	116 vs. 118	212/234	46.3 ± 9.4	232/2/0	195/234	N/A	234/234	N/A	Lipiodol, epirubicin, mitomycin, carboplatin	N/A
Xu 2012 [38]	China	59 vs. 58	101/117	50.7 ± 9.5	N/A	55/117	3 ± 1.2	9/117	N/A	Lipiodol, epirubicin, 5-fluoruracile hydroxycamptothecin	N/A
Zhong 2009 [39]	China	57 vs. 58	102/115	47.9 ± 10.8	114/1/0	105/115	9.6 ± 3.7	48/115	86/115	Lipiodol, carboplatin, mitomycin, epirubicin	N/A

CPS: Child–Pugh score; N/A: not available; MVI: microvascular invasion; TACE: transarterial chemoembolization.